Oryzon Genomics SA - ESG Rating & Company Profile powered by AI
This SDG score for Oryzon Genomics SA represents the company's reporting of the United Nations Sustainable Development Goals. The ESG rating covers 17 United Nations SDGs including: 'Good Health & Wellbeing', 'Responsible Production & Consumption' and 'Life on Land'. This page contains a zero-cost E,S&G analysis covering Oryzon Genomics SA.
Oryzon Genomics SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.7; made up of an environmental score of 2.7, social score of 6.4 and governance score of 8.0.
5.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 541 | Wntresearch AB | 5.8 | High |
| 541 | Zenotech Laboratories Ltd | 5.8 | High |
| 579 | Oryzon Genomics SA | 5.7 | High |
| 579 | Caplin Point Laboratories Ltd | 5.7 | High |
| 579 | Biotest AG | 5.7 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Oryzon Genomics SA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Oryzon Genomics SA disclose current and historical energy intensity?
Sign up for free to unlockDoes Oryzon Genomics SA report the average age of the workforce?
Sign up for free to unlockDoes Oryzon Genomics SA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Oryzon Genomics SA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Oryzon Genomics SA disclose cybersecurity risks?
Sign up for free to unlockDoes Oryzon Genomics SA offer flexible work?
Sign up for free to unlockDoes Oryzon Genomics SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Oryzon Genomics SA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Oryzon Genomics SA conduct supply chain audits?
Sign up for free to unlockDoes Oryzon Genomics SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Oryzon Genomics SA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Oryzon Genomics SA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Oryzon Genomics SA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Oryzon Genomics SA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Oryzon Genomics SA disclose water use targets?
Sign up for free to unlockDoes Oryzon Genomics SA have careers partnerships with academic institutions?
Sign up for free to unlockDid Oryzon Genomics SA have a product recall in the last two years?
Sign up for free to unlockDoes Oryzon Genomics SA disclose incidents of discrimination?
Sign up for free to unlockDoes Oryzon Genomics SA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Oryzon Genomics SA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Oryzon Genomics SA disclose parental leave metrics?
Sign up for free to unlockDoes Oryzon Genomics SA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Oryzon Genomics SA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Oryzon Genomics SA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Oryzon Genomics SA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Oryzon Genomics SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Oryzon Genomics SA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Oryzon Genomics SA involved in embryonic stem cell research?
Sign up for free to unlockDoes Oryzon Genomics SA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Oryzon Genomics SA disclose its waste policy?
Sign up for free to unlockDoes Oryzon Genomics SA report according to TCFD requirements?
Sign up for free to unlockDoes Oryzon Genomics SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Oryzon Genomics SA disclose energy use targets?
Sign up for free to unlockDoes Oryzon Genomics SA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Oryzon Genomics SA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Oryzon Genomics SA
These potential risks are based on the size, segment and geographies of the company.
Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.